Prognostic significance of epidermal growth factor receptor overexpression in pancreas cancer and nodal metastasis

ANZ Journal of Surgery

Volumn 85, Issue 3, 2015, Pages 174-178

  Perini, Marcos Vinicius ^a   Montagnini, Andre Luis ^a   Coudry, Renata ^b   Patzina, Rosely ^a   Penteado, Sonia ^a   Abdo, Emilio Elias ^a   Diniz, Alessandro ^b   Jukemura, Jose ^a   da Cunha, Jose Eduardo Monteiro ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b A C CAMARGO CANCER CENTER   (Brazil)

Author keywords

Cancer; EGFR; Pancreas; Surgery; Survival

Indexed keywords

EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; TUMOR MARKER;

ADENOCARCINOMA; ADULT; AGED; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; METABOLISM; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PANCREAS RESECTION; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; PATHOLOGY; PROGNOSIS; SURVIVAL; TREATMENT OUTCOME; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PANCREATECTOMY; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84924003878     PISSN: 14451433     EISSN: 14452197     Source Type: Journal    
DOI: 10.1111/ans.12399     Document Type: Article

References (28)

1. Witkowski ER, Smith JK, Tseng JF. Outcomes following resection of pancreatic cancer. J. Surg. Oncol. 2013; 107: 97-103.
2. Malleo G, Marchegiani G, Salvia R, Butturini G, Pederzoli P, Bassi C. Pancreaticoduodenectomy for pancreatic cancer: the Verona experience. Surg. Today 2011; 41: 463-470.
3. Bao PQ, Ramanathan RK, Krasinkas A etal. Phase II study of gemcitabine and erlotinib as adjuvant therapy for patients with resected pancreatic cancer. Ann. Surg. Oncol. 2011; 18: 1122-1129.
4. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N. Engl. J. Med. 2008; 358: 1160-1174.
5. Uegaki K, Nio Y, Inoue Y etal. Clinicopathological significance of epidermal growth factor and its receptor in human pancreatic cancer. Anticancer Res. 1997; 17: 3841-3847.
6. Yamanaka Y, Friess H, Kobrin MS etal. Overexpression of HER2/neu oncogene in human pancreatic carcinoma. Hum. Pathol. 1993; 24: 1127-1134.
7. Dong M, Nio Y, Guo KJ, Tamura K, Tian YL, Dong YT. Epidermal growth factor and its receptor as prognostic indicators in Chinese patients with pancreatic cancer. Anticancer Res. 1998; 18: 4613-4619.
8. Tobita K, Kijima H, Dowaki S etal. Epidermal growth factor receptor expression in human pancreatic cancer: significance for liver metastasis. Int. J. Mol. Med. 2003; 11: 305-309.
9. Tsiambas E, Karameris A, Lazaris AC etal. EGFR alterations in pancreatic ductal adenocarcinoma: a chromogenic in situ hybridization analysis based on tissue microarrays. Hepatogastroenterology 2006; 53: 452-457.
10. Smeenk HG, Erdmann J, van Dekken H etal. Long-term survival after radical resection for pancreatic head and ampullary cancer: a potential role for the EGF-R. Dig. Surg. 2007; 24: 38-45.
11. Ueda S, Fukamachi K, Matsuoka Y etal. Ductal origin of pancreatic adenocarcinomas induced by conditional activation of a human Ha-ras oncogene in rat pancreas. Carcinogenesis 2006; 27: 2497-2510.
12. Bloomston M, Bhardwaj A, Ellison EC, Frankel WL. Epidermal growth factor receptor expression in pancreatic carcinoma using tissue microarray technique. Dig. Surg. 2006; 23: 74-79.
13. Chadha KS, Khoury T, Yu J etal. Activated Akt and Erk expression and survival after surgery in pancreatic carcinoma. Ann. Surg. Oncol. 2006; 13: 933-939.
14. Takikita M, Altekruse S, Lynch CF etal. Associations between selected biomarkers and prognosis in a population-based pancreatic cancer tissue microarray. Cancer Res. 2009; 69: 2950-2955.
15. Mahipal A, McDonald MJ, Witkiewicz A, Carr BI. Cell membrane and cytoplasmic epidermal growth factor receptor expression in pancreatic ductal adenocarcinoma. Med. Oncol. 2012; 29: 134-139.
16. Einama T, Ueda S, Tsuda H etal. Membranous and cytoplasmic expression of epidermal growth factor receptor in metastatic pancreatic ductal adenocarcinoma. Exp. Ther. Med. 2012; 3: 931-936.
17. Gerlinger M, Rowan AJ, Horswell S etal. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 2012; 366: 883-892.
18. Hamilton SR, Aaltonen LA (eds). World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Digestive System. Lyon: IARC Press, 2000.
19. Fedor HL, De Marzo AM. Practical methods for tissue microarray construction. Methods Mol. Med. 2005; 103: 89-101.
20. Deng Y, Kurland BF, Wang J etal. High epidermal growth factor receptor expression in metastatic colorectal cancer lymph nodes may be more prognostic of poor survival than in primary tumor. Am. J. Clin. Oncol. 2009: 32; 245-252.
21. Moore MJ, Goldstein D, Hamm J etal. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 2007; 25: 1960-1966.
22. Philip PA, Benedetti J, Corless CL etal. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J. Clin. Oncol. 2010; 28: 3605-3610.
23. Xiong HQ, Rosenberg A, LoBuglio A etal. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J. Clin. Oncol. 2004; 22: 2610-2616.
24. Boeck S, Jung A, Laubender RP etal. EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104. Br. J. Cancer 2013; 108: 469-476.
25. Atkins D, Reiffen KA, Tegtmeier CL, Winther H, Bonato MS, Storkel S. Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J. Histochem. Cytochem. 2004; 52: 893-901.
26. Liu D, Aguirre Ghiso J, Estrada Y, Ossowski L. EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell 2002; 1: 445-457.
27. Valsecchi ME, McDonald M, Brody JR etal. Epidermal growth factor receptor and insulinlike growth factor 1 receptor expression predict poor survival in pancreatic ductal adenocarcinoma. Cancer 2012; 118: 3484-3493.
28. Perini MV, Montagnini AL, Jukemura J etal. Clinical and pathologic prognostic factors for curative resection for pancreatic cancer. HPB (Oxford) 2008; 10: 356-362.